Kinder, gentler treatments for older, sicker patients
By Anette Breindl
Monday, December 9, 2013
NEW ORLEANS – Data from much-anticipated studies were revealed at Sunday’s plenary session at the American Society of Hematology’s 55th annual meeting. One was the head-to-head comparison of Genentech Inc./Roche AG’s Gazyva (obinutuzumab/GA101) with Rituxan (rituximab, Biogen Idec.) for the treatment of chronic lymphocytic leukemia (CLL). The other were the results of the FIRST/ MM020 trial comparing Revlimid (lenalidomide, Celgene Corp.) plus dexamethasone to the standard treatment of Melphalan, prednisone and thalidomide (MPT) in stem cell transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. Both drugs spell progress for patients in part because they are less toxic than current regimens.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.